Dashboard
1
Poor Management Efficiency with a low ROCE of 6.73%
- The company has been able to generate a Return on Capital Employed (avg) of 6.73% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -2.91% and Operating profit at 29.38% over the last 5 years
4
Negative results in Jun 26
5
With ROE of 3.77%, it has a expensive valuation with a 1.83 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,445 Million (Mid Cap)
49.00
NA
0.00%
1.56
3.77%
2.65
Revenue and Profits:
Net Sales:
2,556 Million
(Quarterly Results - Jun 2026)
Net Profit:
18 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.53%
0%
9.53%
6 Months
-13.55%
0%
-13.55%
1 Year
-34.69%
0%
-34.69%
2 Years
-34.08%
0%
-34.08%
3 Years
-67.96%
0%
-67.96%
4 Years
-39.55%
0%
-39.55%
5 Years
-3.67%
0%
-3.67%
Chongqing Taiji Industry (Group) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.91%
EBIT Growth (5y)
29.38%
EBIT to Interest (avg)
2.76
Debt to EBITDA (avg)
5.06
Net Debt to Equity (avg)
1.36
Sales to Capital Employed (avg)
1.38
Tax Ratio
45.88%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.21%
ROE (avg)
8.70%
Valuation key factors
Factor
Value
P/E Ratio
49
Industry P/E
Price to Book Value
1.83
EV to EBIT
55.12
EV to EBITDA
20.72
EV to Capital Employed
1.32
EV to Sales
1.19
PEG Ratio
0.21
Dividend Yield
NA
ROCE (Latest)
2.40%
ROE (Latest)
3.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
2,556.10
2,528.40
1.10%
Operating Profit (PBDIT) excl Other Income
188.30
203.20
-7.33%
Interest
31.60
26.70
18.35%
Exceptional Items
0.00
0.00
Consolidate Net Profit
18.00
66.00
-72.73%
Operating Profit Margin (Excl OI)
27.20%
33.30%
-0.61%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 1.10% vs 4.81% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -72.73% vs 253.13% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
10,448.10
12,303.30
-15.08%
Operating Profit (PBDIT) excl Other Income
812.50
888.80
-8.58%
Interest
138.20
142.80
-3.22%
Exceptional Items
-73.60
-14.20
-418.31%
Consolidate Net Profit
120.60
51.30
135.09%
Operating Profit Margin (Excl OI)
32.10%
36.00%
-0.39%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -15.08% vs -20.28% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 135.09% vs -93.99% in Dec 2024
About Chongqing Taiji Industry (Group) Co., Ltd. 
Chongqing Taiji Industry (Group) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






